From StockTwits: 2025-04-14 21:56:00

Mirum Pharmaceuticals, Inc. announced FDA approval for Livmarli tablets to treat cholestatic pruritus in patients with certain liver diseases. The tablets will be available in June through Mirum Access Plus pharmacy. Livmarli is an orally administered ileal bile acid transporter inhibitor used for Alagille syndrome and Progressive Familial Intrahepatic Cholestasis. In 2024, Livmarli’s net sales totaled $213.3 million. Retail sentiment around Mirum Pharmaceuticals is bullish on Stocktwits, with a user suggesting potential to touch $60. MIRM stock is down 6% year-to-date but has gained 64% over the past 12 months.



Read more at StockTwits: FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish